Literature DB >> 17000217

Antibiotic therapy and 48-hour mortality for patients with pneumonia.

Eric M Mortensen1, Marcos I Restrepo, Antonio Anzueto, Jacqueline A Pugh.   

Abstract

PURPOSE: Although numerous articles have demonstrated that recommended empiric antimicrobial regimens are associated with decreased mortality at 30 days, there is controversy over whether appropriate antibiotic selection has a beneficial impact on mortality within the first 48 to 96 hours after admission. Our aim was to determine whether the use of guideline-concordant antibiotic therapy is associated with decreased mortality within the first 48 hours after admission for patients with pneumonia.
METHODS: A retrospective cohort study was conducted at two tertiary teaching hospitals in San Antonio, Texas. A propensity score was used to balance the covariates associated with the use of guideline-concordant antimicrobial therapy. A multivariable logistic regression model was used to assess the association between mortality within 48 hours and the use of guideline-concordant antibiotic therapy, after adjusting for potential confounders including the propensity score.
RESULTS: Information was obtained on 787 patients with community-acquired pneumonia. The median age was 60 years, 79% were male, and 20% were initially admitted to the intensive care unit. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk. Within the first 48 hours, 20 patients died. After adjustment for potential confounders, the use of guideline-concordant antimicrobial therapy (odds ratio 0.37, 95% confidence interval, 0.14-0.95) was significantly associated with decreased mortality at 48 hours after admission.
CONCLUSION: Using initial empiric guideline-concordant antimicrobial therapy is associated with decreased mortality at 48 hours. Further research needs to investigate methods to ensure that patients with community-acquired pneumonia are treated with appropriate antimicrobial therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000217     DOI: 10.1016/j.amjmed.2006.04.017

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Comparison of Patients with Community-Acquired Pneumonia Who Did and Did not Receive Treatment in Accordance with the 2009 Pneumonia Guideline of Turkish Thoracic Society.

Authors:  Öznur Kılıç Soylar; Oğuz Kılınç; Hülya Ellidokuz
Journal:  Turk Thorac J       Date:  2015-04-01

2.  Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community Study.

Authors:  Sara Tomczyk; Seema Jain; Anna M Bramley; Wesley H Self; Evan J Anderson; Chris Trabue; D Mark Courtney; Carlos G Grijalva; Grant W Waterer; Kathryn M Edwards; Richard G Wunderink; Lauri A Hicks
Journal:  Open Forum Infect Dis       Date:  2017-06-20       Impact factor: 3.835

3.  Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.

Authors:  Ana Motos; Gianluigi Li Bassi; Francesco Pagliara; Laia Fernandez-Barat; Hua Yang; Eli Aguilera Xiol; Tarek Senussi; Francesco A Idone; Chiara Travierso; Chiara Chiurazzi; Rosanel Amaro; Minlan Yang; Joaquim Bobi; Montserrat Rigol; David P Nicolau; Gerard Frigola; Roberto Cabrera; Jose Ramirez; Paolo Pelosi; Francesco Blasi; Massimo Antonelli; Antonio Artigas; Jordi Vila; Marin Kollef; Antoni Torres
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

4.  Variation in antibiotic treatment for diabetic patients with serious foot infections: a retrospective observational study.

Authors:  Benjamin G Fincke; Donald R Miller; Cindy L Christiansen; Robin S Turpin
Journal:  BMC Health Serv Res       Date:  2010-07-06       Impact factor: 2.655

5.  Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia.

Authors:  M Schlueter; C James; A Dominguez; L Tsu; G Seymann
Journal:  Infection       Date:  2010-07-21       Impact factor: 3.553

6.  MicroDSC study of Staphylococcus epidermidis growth.

Authors:  Dragos C Zaharia; Cezar Iancu; Alexandru T Steriade; Alexandru A Muntean; Octavian Balint; Vlad T Popa; Mircea I Popa; Miron A Bogdan
Journal:  BMC Microbiol       Date:  2010-12-17       Impact factor: 3.605

7.  Compliance with guidelines-recommended processes in pneumonia: impact of health status and initial signs.

Authors:  Rosario Menéndez; Antoni Torres; Soledad Reyes; Rafael Zalacain; Alberto Capelastegui; Olga Rajas; Luis Borderías; Juan J Martín-Villasclaras; Salvador Bello; Inmaculada Alfageme; Felipe Rodríguez de Castro; Jordi Rello; Luis Molinos; Juan Ruiz-Manzano
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

8.  Diagnostic use of lung ultrasound compared to chest radiograph for suspected pneumonia in a resource-limited setting.

Authors:  Yogendra Amatya; Jordan Rupp; Frances M Russell; Jason Saunders; Brian Bales; Darlene R House
Journal:  Int J Emerg Med       Date:  2018-03-12

Review 9.  Diagnosis and treatment of severe sepsis.

Authors:  Yann-Erick Claessens; Jean-François Dhainaut
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

10.  Immunoactivating peptide p4 augments alveolar macrophage phagocytosis in two diverse human populations.

Authors:  Mathieu Bangert; Adam K Wright; Jamie Rylance; Matthew J Kelly; Angela D Wright; George M Carlone; Jacquelyn S Sampson; Gowrisankar Rajam; Edwin W Ades; Aras Kadioglu; Stephen B Gordon
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.